ArticleRadiology and oncology2026

Real-world data survival outcomes of first line immunotherapy with pembrolizumab in high expressers with stage IV non-small cell lung cancer.

Vladimir Stojsic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.